Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae

Infection and Immunity

Volumn 67, Issue 7, 1999, Pages 3587-3592

  Seong, Seung Yong ^a,b   Cho, Nam Hyuk ^a,b   Kwon, Ick Chan ^a   Jeong, Seo Young ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; DRUG FORMULATION; FEMALE; IMMUNOGENICITY; INFECTION RESISTANCE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0032968051     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.7.3587-3592.1999     Document Type: Article

References (34)

1. Ammann, A. J., G. Schiffman, D. Abrams, P. Volberding, J. Ziegler, and M. Conant. 1984. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA 251:1447-1449.
2. Arranz, E., S. O'Mahoney, J. R. Barton, and A. Ferguson. 1992. Immunosenescence and mucosal immunity: significant effects of old age on secretory IgA concentrations and intraepithelial lymphocyte counts. Gut 33:882-886.
3. Barington, T., M. Skettrup, L. Juul, and C. Heilmann. 1993. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect. Immun. 61:432-438.
4. Bergquist, C., T. Lagergard, and J. Holmgren. 1997. Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect. Immun. 65:1579-1583.
5. Bergquist, C., T. Lagergard, M. Lindblad, and J. Holmgren. 1995. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect. Immun. 63:2021-2025.
6. Beuvery, E. C., F. van Rossum, and J. Nagel. 1982. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect. Immun. 37:15-22.
7. Cho, N. H., S. Y. Seong, K. H. Cheon, Y. H. Kim, I. C. Kwon, and S. Y. Jeong. 1998. A novel mucosal immunization with polysaccharide-protein conjugates entrapped in alginate microsphere. J. Controlled Release 53:215-224.
8. Cundell, D. R., N. P. Gerard, C. Gerard, I. Idanpaan-Heikkila, and E. I. Tuomanen. 1995. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 377:435-438.
9. Elson, C. O., W. Ealding, and J. Lefkowitz. 1984. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. J. Immunol. Methods 67:101-108.
10. Eriksson, K., A. Kilander, L. Hagberg, G. Norkrans, J. Holmgren, and C. Czerkinsky. 1995. Intestinal immune responsiveness in HIV-infected individuals. Adv. Exp. Med. Biol. 371:1011-1014.
11. Holmgren, J., C. Czerkinsky, N. Lycke, and A. M. Svennerholm. 1994. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Am. J. Trop. Med. Hyg. 50:42-54.
12. Horan, M. A. 1993. Immunosenescence and mucosal immunity. Lancet 341: 793-794.
13. Janoff, E. N., R. F. Breiman, C. L. Daley, and P. C. Hopewell. 1992. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann. Intern. Med. 117:314-324.
14. Janoff, E. N., J. M. Douglas, Jr., M. Gabriel, M. J. Blaser, A. J. Davidson, D. L. Cohn, and F. N. Judson. 1988. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J. Infect. Dis. 158:983-990.
15. Laferriere, C. A., R. K. Sood, J. M. de Muys, F. Michon, and H. J. Jennings. 1997. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine 15:179-186.
16. Lebens, M., V. Shahabi, M. Backstrom, T. Houze, N. Lindblad, and J. Holmgren. 1996. Synthesis of hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits: potential for use in a broad-spectrum vaccine. Infect. Immun. 64:2144-2150.
17. Lewis, D. J., C. F. Gilks, S. Ojoo, L. R. Castello-Branco, G. Dougan, M. R. Evans, S. McDermott, and G. E. Griffin. 1994. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS 8:779-785.
18. Leliger, A. E., G. T. Rijkers, P. Aerts, A. Been-Tiktak, A. I. Hoepelman, H. van Dijk, and J. C. Borleffs. 1995. Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients. FEMS Immunol. Med. Microbiol. 12:33-41.
19. Marx, P. A., R. W. Compans, A. Gettie, J. K. Staas, R. M. Gilley, M. J. Mulligan, G. V. Yamschikov, D. Chen, and J. H. Eldridge. 1993. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 260:1323-1327.
20. Mathiowitz, E., J. S. Jacob, Y. S. Jong, G. P. Carino, D. E. Chickering, P. Chaturvedi, C. A. Santos, K. Vijayaraghavan, S. Montgomery, M. Bassett, and C. Morrell. 1997. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386:410-414.
21. Mestecky, J., and J. R. McGhee. Prospects for human mucosal vaccines. 1992. Adv. Exp. Med. Biol. 327:13-23.
22. Morris, W., M. C. Steinhoff, and P. K. Russell. 1994. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 12:5-11.
23. Murray, H. W., R. A. Gellene, D. M. Libby, C. D. Rothermel, and B. Y. Rubin. 1985. Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma. J. Immunol. 135:2374-2377.
24. Neu, H. C. 1992. The crisis in antibiotic resistance. Science 257:1064-1073.
25. O'Hagan, D. T., H. Jeffery, M. J. Roberts, J. P. McGee, and S. S. Davis. 1991. Controlled release microparticles for vaccine development. Vaccine 9:768-771.
26. Opstad, N. L., C. L. Daley, J. R. Thurn, J. B. Rubins, C. Merrifield, P. C. Hopewell, and E. N. Janoff. 1995. Impact of Streptococcus pneumoniae bacteremia and human immunodeficiency virus type 1 on oral mucosal immunity. J. Infect. Dis. 172:566-570.
27. Peeters, C. C., A. M. Tenbergen-Meekes, D. E. Evenberg, J. T. Poolman, B. J. Zegers, and G. T. Rijkers. 1991. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J. Immunol. 146:4308-4314.
28. Peters, V. B., E. P. Diamant, D. S. Hodes, and C. O. Cimino. 1994. Impaired immunity to pneumococcal polysaccharide antigens in children with human immunodeficiency virus infection immunized with pneumococcal vaccine. Pediatr. Infect. Dis. J. 13:933-934.
29. Rognum, T. O., S. Thrane, L. Stoltenberg, A. Vege, and P. Brandtzaeg. 1992. Development of intestinal mucosal immunity in fetal life and the first postnatal months. Pediatr. Res. 32:145-149.
30. Service, R. F. 1994. Triggering the first line of defense. Science 265:1522-1524.
31. Siber, G. R. 1994. Pneumococcal disease: prospects for a new generation of vaccines. Science 265:1385-1387.
32. Simberkoff, M. S., W. El Sadr, G. Schiffman, and J. J. Rahal, Jr. 1984. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. Am. Rev. Respir. Dis. 130:1174-1176.
33. Szewczuk, M. R., R. J. Campbell, and L. K. Jung. 1981. Lack of age-associated immune dysfunction in mucosal-associated lymph nodes. J. Immunol. 126:2200-2204.
34. Weiser, J. N., R. Austrian, P. K. Sreenivasan, and H. R. Masure. 1994. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect. Immun. 62:2582-2589.